Deutsche Bank
LOGC

Deutsche Bank’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Deutsche Bank’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,714
Closed -$78K – 4929
2021
Q1 		$78K Sell
10,714
-1,007
-9% -$8.29K ﹤0.01% 4103
2020
Q4 		$90K Buy
11,721
+4,681
+66% +$31.3K ﹤0.01% 3901
2020
Q3 		$64K Buy
7,040
+585
+9% +$4.44K ﹤0.01% 3762
2020
Q2 		$55K Buy
6,455
+3,608
+127% +$23.7K ﹤0.01% 3774
2020
Q1 		$14K Sell
2,847
-2,656
-48% -$20.7K ﹤0.01% 3993
2019
Q4 		$38K Buy
5,503
+3,095
+129% +$28K ﹤0.01% 4080
2019
Q3 		$24K Sell
2,408
-4,118
-63% -$44K ﹤0.01% 4264
2019
Q2 		$83K Sell
6,526
-3,686
-36% -$48.9K ﹤0.01% 4300
2019
Q1 		$99K Sell
10,212
-976
-9% -$9.09K ﹤0.01% 4319
2018
Q4 		$115K Buy
+11,188
New +$135K ﹤0.01% 4160

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Deutsche Bank's LOGC Position: Q2 2021 in Review

Deutsche Bank sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 10,714 shares — an estimated $78K sold.

Deutsche Bank first reported a position in LOGC in Q4 2018 and held it in 10 quarters. The position peaked at $115K in Q4 2018. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

  • Deutsche Bank reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Deutsche Bank sold 10,714 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $78K.
  • Deutsche Bank first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 10 quarters.
  • Deutsche Bank's LogicBio Therapeutics, Inc. Common Stock position peaked at $115K in Q4 2018.
  • 63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Deutsche Bank's 13F filing for Q2 2021, filed 11 Aug 2021.